{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:13:29Z","timestamp":1792019609435,"version":"4.4.0"},"reference-count":58,"publisher":"American Association for Cancer Research (AACR)","issue":"2","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K16173"],"award-info":[{"award-number":["22K16173"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["25K19440"],"award-info":[{"award-number":["25K19440"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Okayama Health Foundation"},{"DOI":"10.13039\/501100013171","name":"Ryobi Teien Memory Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015642","name":"Japan Lung Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015642","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Teraoka Scholarship Foundation"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Some anaplastic lymphoma kinase (ALK) gene rearrangement\u2013positive lung cancers show early resistance, within 3 months, to alectinib. This study investigated the clinical and molecular characteristics of these patients. We analyzed patients with unresectable stage III\/IV disease without indications for radical radiotherapy and recurrent ALK-positive lung cancer who received alectinib as the primary ALK tyrosine kinase inhibitor between 2013 and 2021 at nine hospitals. In total, 103 patients were included. The median age was 65 years; 44 were male and 22 had brain metastases. The median progression-free survival and overall survival (OS) were 28.7 and 80.6 months. Nineteen patients treated for \u22643 months and 84 treated for &amp;gt;3 months were categorized into the early resistance and responder groups, respectively. The early resistance group had significantly shorter OS (8.4 months vs. not estimable, P &amp;lt; 0.001) and was significantly more likely to have brain metastases (42% vs. 17%, P = 0.027). They also showed elevated inflammatory markers, including neutrophil-to-lymphocyte ratio (NLR). Univariate analysis identified brain metastases and high NLR as significant predictors of early resistance. Spatial transcriptome analysis and immunohistochemical staining revealed upregulation of annexin A1 (ANXA1), a calcium-dependent phospholipid-binding protein involved in inflammation and cancer progression, in the early resistance group. Interleukin 6 stimulation, prompted by elevated inflammatory markers, increased ANXA1 expression and reduced alectinib sensitivity. Knockdown of ANXA1 improved alectinib sensitivity in alectinib-resistant cells. In conclusion, brain metastases and high NLR are associated with early resistance. ANXA1 may play an important role in mediating early resistance. New treatment options for the early resistance group are required.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Some ALK-positive lung cancers show early resistance to alectinib. This study found brain metastases and elevated NLR associated with early resistance. Spatial transcriptomics and functional analysis suggested involvement of ANXA1. These results reveal clinical and molecular biomarkers that may guide treatment strategies for early resistance to alectinib.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0545","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T21:38:54Z","timestamp":1768340334000},"page":"284-293","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical Characteristics and Spatial Transcriptome Analysis of Non\u2013Small Cell Lung Cancers Exhibiting Early Alectinib Resistance: A Retrospective OLCSG Study"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6305-7126","authenticated-orcid":false,"given":"Tadahiro","family":"Kuribayashi","sequence":"first","affiliation":[{"name":"1Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0638-8435","authenticated-orcid":false,"given":"Go","family":"Makimoto","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/019tepx80","id-type":"ROR","asserted-by":"publisher"}],"name":"Okayama University Hospital 2 Department of Respiratory Medicine, , Okayama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5180-3933","authenticated-orcid":false,"given":"Kadoaki","family":"Ohashi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/019tepx80","id-type":"ROR","asserted-by":"publisher"}],"name":"Okayama University Hospital 2 Department of Respiratory Medicine, , Okayama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3786-936X","authenticated-orcid":false,"given":"Shuta","family":"Tomida","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/019tepx80","id-type":"ROR","asserted-by":"publisher"}],"name":"Okayama University Hospital 3 Center for Comprehensive Genomic Medicine, , Okayama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4413-5746","authenticated-orcid":false,"given":"Hirofumi","family":"Inoue","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/019tepx80","id-type":"ROR","asserted-by":"publisher"}],"name":"Okayama University Hospital 3 Center for Comprehensive Genomic Medicine, , Okayama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5595-5010","authenticated-orcid":false,"given":"Toshihide","family":"Yokoyama","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00947s692","id-type":"ROR","asserted-by":"publisher"}],"name":"Kurashiki Central Hospital 4 Department of Respiratory Medicine, Ohara Healthcare Foundation, , Kurashiki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6079-3511","authenticated-orcid":false,"given":"Shoichi","family":"Kuyama","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03kcxpp45","id-type":"ROR","asserted-by":"publisher"}],"name":"NHO Iwakuni Clinical Center 5 Department of Respiratory Medicine, , Iwakuni, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0538-5052","authenticated-orcid":false,"given":"Yuka","family":"Kato","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03yk8xt33","id-type":"ROR","asserted-by":"publisher"}],"name":"Shikoku Cancer Center 6 Department of Thoracic Oncology and Medicine, National Hospital Organization, , Matsuyama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6238-7998","authenticated-orcid":false,"given":"Kenichiro","family":"Kudo","sequence":"additional","affiliation":[{"name":"7Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Okayama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2546-5920","authenticated-orcid":false,"given":"Naokatsu","family":"Horita","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03adh2020","id-type":"ROR","asserted-by":"publisher"}],"name":"Kure Kyosai Hospital 8 Department of Respiratory Medicine, , Kure, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4418-3131","authenticated-orcid":false,"given":"Hiroe","family":"Kayatani","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02h70he60","id-type":"ROR","asserted-by":"publisher"}],"name":"Japanese Red Cross Okayama Hospital 9 Department of Respiratory Medicine, , Okayama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7830-5082","authenticated-orcid":false,"given":"Masaaki","family":"Inoue","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/027f9rb06","id-type":"ROR","asserted-by":"publisher"}],"name":"Shimonoseki City Hospital 10 Department of Chest Surgery, , Shimonoseki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3513-3214","authenticated-orcid":false,"given":"Keisuke","family":"Sugimoto","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qd25655","id-type":"ROR","asserted-by":"publisher"}],"name":"Japanese Red Cross Kobe Hospital 11 Department of Respiratory Medicine, , Kobe, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2134-2865","authenticated-orcid":false,"given":"Kiichiro","family":"Ninomiya","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/019tepx80","id-type":"ROR","asserted-by":"publisher"}],"name":"Okayama University Hospital 3 Center for Comprehensive Genomic Medicine, , Okayama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1634-5487","authenticated-orcid":false,"given":"Yoshinobu","family":"Maeda","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9910-0164","authenticated-orcid":false,"given":"Yosuke","family":"Togashi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/019tepx80","id-type":"ROR","asserted-by":"publisher"}],"name":"Okayama University Hospital 2 Department of Respiratory Medicine, , Okayama, Japan."},{"id":[{"id":"https:\/\/ror.org\/02pc6pc55","id-type":"ROR","asserted-by":"publisher"}],"name":"Okayama University 12 Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, , Okayama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0112-0843","authenticated-orcid":false,"given":"Katsuyuki","family":"Hotta","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/019tepx80","id-type":"ROR","asserted-by":"publisher"}],"name":"Okayama University Hospital 13 Center for Innovative Clinical Medicine, , Okayama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"2026020602020285400_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2026020602020285400_bib2","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2147\/CLEP.S69718","article-title":"Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors","volume":"6","author":"Chia","year":"2014","journal-title":"Clin Epidemiol"},{"key":"2026020602020285400_bib3","doi-asserted-by":"crossref","first-page":"102178","DOI":"10.1016\/j.ctrv.2021.102178","article-title":"Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer","volume":"95","author":"Remon","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"2026020602020285400_bib4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","article-title":"Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial","volume":"390","author":"Hida","year":"2017","journal-title":"Lancet"},{"key":"2026020602020285400_bib5","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"key":"2026020602020285400_bib6","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1016\/j.jtho.2019.07.017","article-title":"Rapid acquisition of alectinib resistance in ALK-positive lung cancer with high tumor mutation burden","volume":"14","author":"Makimoto","year":"2019","journal-title":"J Thorac Oncol"},{"key":"2026020602020285400_bib7","doi-asserted-by":"crossref","first-page":"713530","DOI":"10.3389\/fonc.2021.713530","article-title":"The resistance mechanisms and treatment strategies for ALK-rearranged non-small cell lung cancer","volume":"11","author":"Pan","year":"2021","journal-title":"Front Oncol"},{"key":"2026020602020285400_bib8","first-page":"371","article-title":"Anaplastic lymphoma kinase fusion: a review of therapeutic drugs and treatment strategies","volume":"74","author":"Makimoto","year":"2020","journal-title":"Acta Med Okayama"},{"key":"2026020602020285400_bib9","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.3390\/diagnostics11122170","article-title":"Prognostic markers of survival among Japanese patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer receiving first-line alectinib","volume":"11","author":"Takeda","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"2026020602020285400_bib10","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/ajco.13284","article-title":"The value of blood biomarkers of progression and prognosis in ALK-positive patients with non-small cell lung cancer treated with crizotinib","volume":"16","author":"Yang","year":"2020","journal-title":"Asia Pac J Clin Oncol"},{"key":"2026020602020285400_bib11","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.21037\/tlcr-22-857","article-title":"Efficacy and safety of alectinib in ALK-positive non-small cell lung cancer and blood markers for prognosis and efficacy: a retrospective cohort study","volume":"11","author":"Jiang","year":"2022","journal-title":"Transl Lung Cancer Res"},{"key":"2026020602020285400_bib12","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41392-024-01823-2","article-title":"Tumor biomarkers for diagnosis, prognosis and targeted therapy","volume":"9","author":"Zhou","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"2026020602020285400_bib13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41592-020-01033-y","article-title":"Method of the year: spatially resolved transcriptomics","volume":"18","author":"Marx","year":"2021","journal-title":"Nat Methods"},{"key":"2026020602020285400_bib14","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41587-020-0472-9","article-title":"Multiplex digital spatial profiling of proteins and RNA in fixed tissue","volume":"38","author":"Merritt","year":"2020","journal-title":"Nat Biotechnol"},{"key":"2026020602020285400_bib15","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1158\/1078-0432.CCR-20-0175","article-title":"Biomarkers associated with beneficial PD-1 checkpoint blockade in non-small cell lung cancer (NSCLC) identified using high-plex digital spatial profiling","volume":"26","author":"Zugazagoitia","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026020602020285400_bib16","doi-asserted-by":"crossref","first-page":"e004757","DOI":"10.1136\/jitc-2022-004757","article-title":"Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancer","volume":"10","author":"Moutafi","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026020602020285400_bib17","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2026020602020285400_bib18","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1158\/2326-6066.CIR-21-0751","article-title":"CD8+ T-cell responses are boosted by dual PD-1\/VEGFR2 blockade after EGFR inhibition in Egfr-mutant lung cancer","volume":"10","author":"Nishii","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"2026020602020285400_bib19","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1016\/j.jtho.2019.03.009","article-title":"Primary resistance to alectinib was lost after bevacizumab combined chemotherapy in ALK-rearranged lung adenocarcinoma","volume":"14","author":"Nakasuka","year":"2019","journal-title":"J Thorac Oncol"},{"key":"2026020602020285400_bib20","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1002\/sim.7273","article-title":"Firth\u2019s logistic regression with rare events: accurate effect estimates and predictions?","volume":"36","author":"Puhr","year":"2017","journal-title":"Stat Med"},{"key":"2026020602020285400_bib21","first-page":"100157","article-title":"Retrospective real-world outcomes for patients with ALK-rearranged lung cancer receiving ALK receptor tyrosine kinase inhibitors","volume":"2","author":"Gibson","year":"2021","journal-title":"JTO Clin Res Rep"},{"key":"2026020602020285400_bib22","first-page":"100876","article-title":"Characteristics of short-term survivors with ALK or ROS1-altered metastatic NSCLC","volume":"6","author":"Liu","year":"2025","journal-title":"JTO Clin Res Rep"},{"key":"2026020602020285400_bib23","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1038\/sj.bjc.6602248","article-title":"The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small-cell lung cancer","volume":"91","author":"McKeown","year":"2004","journal-title":"Br J Cancer"},{"key":"2026020602020285400_bib24","first-page":"376","article-title":"IL-6, NLR, and SII markers and their relation with alterations in CD8+ T-lymphocyte subpopulations in patients treated for lung adenocarcinoma","volume":"9","author":"Islas-Vazquez","year":"2020","journal-title":"Biology (Basel)"},{"key":"2026020602020285400_bib25","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","article-title":"Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms","volume":"115","author":"Quint\u00e1s-Cardama","year":"2010","journal-title":"Blood"},{"key":"2026020602020285400_bib26","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1634\/theoncologist.2020-0011","article-title":"Real-world treatment patterns and progression-free survival associated with anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor therapies for ALK+ non-small cell lung cancer","volume":"25","author":"Jahanzeb","year":"2020","journal-title":"Oncologist"},{"key":"2026020602020285400_bib27","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1093\/annonc\/mdy405","article-title":"Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study","volume":"29","author":"Gadgeel","year":"2018","journal-title":"Ann Oncol"},{"key":"2026020602020285400_bib28","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.21037\/jtd.2019.03.76","article-title":"Anaplastic lymphoma kinase inhibitors in non-small cell lung cancer patients with brain metastases: a meta-analysis","volume":"11","author":"Zhang","year":"2019","journal-title":"J Thorac Dis"},{"key":"2026020602020285400_bib29","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.3390\/ijms24032242","article-title":"Comparative efficacy of ALK inhibitors for treatment-Na\u00efve ALK-positive advanced non-small cell lung cancer with central nervous system metastasis: a network meta-analysis","volume":"24","author":"Ando","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026020602020285400_bib30","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1200\/JCO.24.00581","article-title":"Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study","volume":"42","author":"Solomon","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026020602020285400_bib31","doi-asserted-by":"crossref","first-page":"100342","DOI":"10.1016\/j.esmoop.2021.100342","article-title":"Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I\/II study","volume":"7","author":"Lin","year":"2022","journal-title":"ESMO Open"},{"key":"2026020602020285400_bib32","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.1038\/s41467-025-59744-9","article-title":"Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial","volume":"16","author":"Arrieta","year":"2025","journal-title":"Nat Commun"},{"key":"2026020602020285400_bib33","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.lungcan.2011.01.002","article-title":"JAK2\/STAT3 signaling pathway activation mediates tumor angiogenesis by upregulation of VEGF and bFGF in non-small-cell lung cancer","volume":"73","author":"Zhao","year":"2011","journal-title":"Lung Cancer"},{"key":"2026020602020285400_bib34","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1158\/1078-0432.CCR-22-1366","article-title":"Molecular mechanisms and future implications of VEGF\/VEGFR in cancer therapy","volume":"29","author":"Patel","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026020602020285400_bib35","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity, inflammation, and cancer","volume":"140","author":"Grivennikov","year":"2010","journal-title":"Cell"},{"key":"2026020602020285400_bib36","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00262-012-1347-9","article-title":"Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy","volume":"62","author":"Yao","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"2026020602020285400_bib37","doi-asserted-by":"crossref","first-page":"886","DOI":"10.21037\/tlcr.2019.11.16","article-title":"Prognostic biomarkers in stage IV non-small cell lung cancer (NSCLC): neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI)","volume":"8","author":"Mandaliya","year":"2019","journal-title":"Transl Lung Cancer Res"},{"key":"2026020602020285400_bib38","doi-asserted-by":"crossref","first-page":"38585","DOI":"10.1038\/srep38585","article-title":"Baseline neutrophil-lymphocyte ratio is associated with baseline and subsequent presence of brain metastases in advanced non-small-cell lung cancer","volume":"6","author":"Koh","year":"2016","journal-title":"Sci Rep"},{"key":"2026020602020285400_bib39","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1475-2891-9-69","article-title":"Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature","volume":"9","author":"Gupta","year":"2010","journal-title":"Nutr J"},{"key":"2026020602020285400_bib40","doi-asserted-by":"crossref","first-page":"5298","DOI":"10.21037\/jtd.2018.08.51","article-title":"Prognostic value of prognostic nutritional index in lung cancer: a meta-analysis","volume":"10","author":"Li","year":"2018","journal-title":"J Thorac Dis"},{"key":"2026020602020285400_bib41","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.pulmoe.2022.11.006","article-title":"Impact of systemic inflammatory markers in patients with ALK-positive non-small cell lung cancer treated with crizotinib","volume":"29","author":"Olmez","year":"2023","journal-title":"Pulmonology"},{"key":"2026020602020285400_bib42","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.3390\/ijms19041045","article-title":"Annexin A1: uncovering the many talents of an old protein","volume":"19","author":"Sheikh","year":"2018","journal-title":"Int J Mol Sci"},{"key":"2026020602020285400_bib43","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.3892\/mmr.2016.5022","article-title":"Knockdown of ANXA1 suppresses the biological behavior of human NSCLC cells in vitro","volume":"13","author":"Fang","year":"2016","journal-title":"Mol Med Rep"},{"key":"2026020602020285400_bib44","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.7314\/APJCP.2014.15.7.3191","article-title":"Regulatory mechanisms of annexin-induced chemotherapy resistance in cisplatin resistant lung adenocarcinoma","volume":"15","author":"Wang","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"2026020602020285400_bib45","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.3390\/cancers13164106","article-title":"The association of annexin A1 and chemosensitivity to osimertinib in lung cancer cells","volume":"13","author":"Chuang","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026020602020285400_bib46","doi-asserted-by":"crossref","first-page":"5757","DOI":"10.1002\/cncr.27565","article-title":"Annexin A1 is associated with gastric cancer survival and promotes gastric cancer cell invasiveness through the formyl peptide receptor\/extracellular signal-regulated kinase\/integrin beta-1-binding protein 1 pathway","volume":"118","author":"Cheng","year":"2012","journal-title":"Cancer"},{"key":"2026020602020285400_bib47","doi-asserted-by":"crossref","first-page":"17590914211001218","DOI":"10.1177\/17590914211001218","article-title":"Knockdown of annexin-A1 inhibits growth, migration and invasion of glioma cells by suppressing the PI3K\/Akt signaling pathway","volume":"13","author":"Wei","year":"2021","journal-title":"ASN Neuro"},{"key":"2026020602020285400_bib48","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0167-4838(00)00154-0","article-title":"Lipocalins and cancer","volume":"1482","author":"Bratt","year":"2000","journal-title":"Biochim Biophys Acta"},{"key":"2026020602020285400_bib49","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/ijc.33711","article-title":"Lipocalin 2 expression promotes tumor progression and therapy resistance by inhibiting ferroptosis in colorectal cancer","volume":"149","author":"Chaudhary","year":"2021","journal-title":"Int J Cancer"},{"key":"2026020602020285400_bib50","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00424-016-1877-7","article-title":"Claudins in cancer: bench to bedside","volume":"469","author":"Osanai","year":"2017","journal-title":"Pflugers Arch"},{"key":"2026020602020285400_bib51","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.3390\/ijms24065494","article-title":"Claudin-4: a new molecular target for epithelial cancer therapy","volume":"24","author":"Fujiwara-Tani","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026020602020285400_bib52","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1111\/cas.14361","article-title":"Targeting claudin-4 enhances chemosensitivity in breast cancer","volume":"111","author":"Luo","year":"2020","journal-title":"Cancer Sci"},{"key":"2026020602020285400_bib53","doi-asserted-by":"crossref","first-page":"e000842","DOI":"10.1136\/jitc-2020-000842","article-title":"Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition","volume":"8","author":"Laino","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026020602020285400_bib54","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1006\/cyto.1997.0325","article-title":"IL-6 stimulates annexin 1 expression and translocation and suggests a new biological role as class II acute phase protein","volume":"10","author":"Solito","year":"1998","journal-title":"Cytokine"},{"key":"2026020602020285400_bib55","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.7150\/jca.52171","article-title":"ANXA1 enhances tumor proliferation and migration by regulating epithelial-mesenchymal transition and IL-6\/JAK2\/STAT3 pathway in papillary thyroid carcinoma","volume":"12","author":"Zhao","year":"2021","journal-title":"J Cancer"},{"key":"2026020602020285400_bib56","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.3390\/cells11101705","article-title":"Interleukin-6 signaling in triple negative breast cancer cells elicits the annexin A1\/formyl peptide receptor 1 axis and affects the tumor microenvironment","volume":"11","author":"Vecchi","year":"2022","journal-title":"Cells"},{"key":"2026020602020285400_bib57","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/s41388-023-02919-9","article-title":"A therapeutic antibody targeting annexin-A1 inhibits cancer cell growth in vitro and in vivo","volume":"43","author":"Al-Ali","year":"2024","journal-title":"Oncogene"},{"issue":"Suppl 16","key":"2026020602020285400_bib58","doi-asserted-by":"crossref","first-page":"TPS2671","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS2671","article-title":"ATTAINMENT: a phase Ib trial of MDX-124, a first-in-class annexin-A1 targeting antibody, alone and in combination with anti-cancer treatments, in patients with advanced solid tumors","volume":"42","author":"Palmer","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0545\/3726226\/crc-25-0545.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/2\/284\/3735458\/crc-25-0545.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/2\/284\/3735458\/crc-25-0545.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T07:02:19Z","timestamp":1770361339000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/2\/284\/772141\/Clinical-Characteristics-and-Spatial-Transcriptome"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,1]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0545","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8295267","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.31274940","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31274937","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31274916","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31274913","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31274946","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31274925","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31274922","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31274934","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31274931","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31274943","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31274919","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31274928","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,1]]}}}